AKT1 and neoplasm: Furthermore, LY294002 (the inhibitor against AKT pathway) treatment significantly suppressed the expression of p-AKTSer473, p-GSK3βSer9 and β-catenin in tumor cells (Fig. 3f and Supplementary Fig. S2C).